News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Treatment Approach in Advanced Melanoma

EP. 1: Introduction to Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 8th 2021

EP. 2: Testing and BRAF Mutations in Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 8th 2021

EP. 3: A Look at the KEYNOTE-054 and COMBI-AD Data

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 15th 2021

EP. 4: Treatment Goals and Patient Decisions in Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 15th 2021

EP. 5: The Role of COVID-19 in Adjuvant Treatment Decisions in Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 22nd 2021

EP. 6: Molecular Testing in Metastatic Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 22nd 2021

EP. 7: Metastatic Melanoma Treatment Decisions

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 29th 2021

EP. 8: Looking at Approved Agents in Metastatic Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

January 29th 2021

EP. 9: Future Directions in Metastatic Melanoma

ByAxel Hauschild, MD, PhD, University Hospital Schleswig-Holstein,Dirk Schadendorf, MD, University Hospital Essen

February 5th 2021

Trending on OncLive

FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer

Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026

Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026

CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026

First-Line Zanubrutinib Is Associated With Improved Real-World Efficacy in Older Patients With CLL